[New Service Announcement] Launch of CTD-ILD-Related Antibody Detection Set

~ Cutting-edge technology enables simultaneous testing for 36 types of antibodies ~

Proteo-Bridge Inc. (Head Office: Koto-ku, Tokyo; CEO: Ryo Kumagai), in collaboration with Fushimi Pharmaceutical Co., Ltd., is pleased to announce the launch of a new contract analysis service for autoantibodies related to CTD-ILD July 1st, 2026.

We sincerely invite all medical professionals and researchers to make use of this service.

[Key Features of the New Service]

• -Simultaneous Detection of 36 Antibodies: In addition to conventional insurance-covered tests, this service includes a comprehensive analysis of multiple CTD-ILD (Connective Tissue Disease-Associated Interstitial Lung Disease) -related autoantibodies newly identified through recent research.

-Utilization of Protein Array Technology: High-precision analysis using the same technology as our research-use testing service “A-Cube®.”

-Please note that this is a research-use only test and cannot be used for diagnostic purposes.

Website: https://fushimi-acube-lab.jp/

[Contact Information for Test Service Inquiries]

Company: Fushimi Pharmaceutical Co., Ltd., Hygiene Testing Center

Phone: +81-877-22-6276

E-mail: th＊fushimi.co.jp

(*Please replace the asterisk with @)

[Inquiries Regarding This Announcement]

Public Relations, Proteo-Bridge Inc.

E-mail: info＊proteo-bridge.co.jp

(*Please replace the asterisk with @)